Clinical Trial Update: Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate Asthma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating single doses of GSK159797 in adults with mild to moderate asthma, focusing on patient safety and lung function.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• GSK159797 (GSK159797)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED